Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage
- 1 June 2007
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 322 (3), 1059-1066
- https://doi.org/10.1124/jpet.107.120147
Abstract
Endocannabinoids are released in response to pathogenic insults, and inhibitors of endocannabinoid inactivation enhance such on-demand responses that promote cellular protection. Here, AM374 (palmitylsulfonyl fluoride), an irreversible inhibitor of fatty acid amide hydrolase (FAAH), was injected i.p. into rats to test for endocannabinoid enhancement. AM374 caused a prolonged elevation of anandamide levels in several brain regions, including the hippocampus, and resulted in rapid activation of the extracellular signal regulated-kinase/mitogen-activated protein kinase pathway that has been linked to survival. To evaluate the neuroprotective nature of the FAAH inhibitor, we tested AM374 in a seizure model involving rats insulted with kainic acid (KA). AM374 was injected immediately after KA administration, and seizure scores were significantly reduced throughout a 4-h observation period. The KA-induced seizures were associated with calpain-mediated cytoskeletal breakdown, reductions in synaptic markers, and loss of CA1 hippocampal neurons. FAAH inhibition protected against the excitotoxic damage and neuronal loss assessed 48 h postinsult. AM374 also preserved pre- and postsynaptic markers to levels comparable with those found in noninsulted animals, and the synaptic marker preservation strongly correlated with reduced seizure scores. With regard to behavioral deficits in the excitotoxic rats, AM374 produced nearly complete functional protection, significantly improving balance and coordination across different behavioral paradigms. These data indicate that AM374 crosses the blood-brain barrier, enhances endocannabinoid responses in key neuronal circuitries, and protects the brain against excitotoxic damage.This publication has 53 references indexed in Scilit:
- Targeting the endocannabinoid system in treating brain disordersExpert Opinion on Investigational Drugs, 2006
- Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide HydrolaseJournal of Neuroscience, 2003
- Survival Signaling and Selective Neuroprotection Through Glutamatergic TransmissionExperimental Neurology, 2002
- Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolaseProceedings of the National Academy of Sciences of the United States of America, 2001
- Endocannabinoids control spasticity in a multiple sclerosis modelThe FASEB Journal, 2000
- Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent MechanismsScience, 1999
- Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective InhibitionScience, 1997
- Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amidesNature, 1996
- Distinct distributions of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor subunits and a related 53,000 Mr antigen (GR53) in brain tissueNeuroscience, 1996
- Glutamate as a hippocampal neuron survival factor: an inherited defect in the trisomy 16 mouse.Proceedings of the National Academy of Sciences of the United States of America, 1995